HIV vaccine research: The way forward

Science

Volumn 321, Issue 5888, 2008, Pages 530-532

  Fauci, Anthony S ^a   Johnston, Margaret I ^a   Dieffenbach, Carl W ^a   Burton, Dennis R ^b   Hammer, Scott M ^c   Hoxie, James A ^d   Martin, Malcolm ^a   Overbaugh, Julie ^e   Watkins, David I ^f   Mahmoud, Adel ^g   Greene, Warner C ^h  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g PRINCETON UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG POL NEF VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120;

HUMAN IMMUNODEFICIENCY VIRUS; RESEARCH; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE COURSE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; BIOMEDICAL RESEARCH; CONTROLLED CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FINANCING, GOVERNMENT; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MALE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); PRIMATES; RESEARCH SUPPORT AS TOPIC; T-LYMPHOCYTES; UNITED STATES; VIRUS REPLICATION;

NORTH AMERICA; UNITED STATES;

PRIMATES;

EID: 48249134364     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1161000     Document Type: Short Survey

References (23)

1. B. D. Walker, D. R. Burton, Science 320, 760 (2008).
2. N. M. Flynn et al., J. Infect. Dis. 191, 654 (2005).
3. P. Pitisuttithum et al., J. Infect. Dis. 194, 1661 (2006).
4. D. R. Burton et al., Nat. Immunol. 5, 233 (2004).
5. G. Pantaleo, R. A. Koup, Nat. Med. 10, 806 (2004).
6. A. J. McMichael, Annu. Rev. Immunol. 24, 227 (2006).
7. M. I. Johnston, A. S. Fauci, N. Engl. J. Med. 356, 2073 (2007).
8. B. F. Haynes, R. J. Shattock, J. Allergy Clin. Immunol. 122, 3 (2008).
9. D. H. Barouch et al., Science 290, 486 (2000).
10. J. J. Mattapallil et al., J. Exp. Med. 203, 1533 (2006).
11. N. A. Wilson et al., J. Virol. 80, 5875 (2006).
12. R. R. Amara et al., Science 292, 69 (2001).
13. J. W. Shiver et al., Nature 415, 331 (2002).
14. N. L. Letvin et al., Science 312, 1530 (2006).
15. D. R. Casimiro et al., J. Virol. 79, 15547 (2005).
16. D. I. Watkins, D. R. Burton, E. G. Kallas, J. P. Moore, W. C. Koff, Nat. Med. 14, 617 (2008).
17. R. Steinbrook, N. Engl. J. Med. 357, 2653 (2007).
18. M. Robertson et al., "Efficacy results from the STEP Study (Merck V520 Protocol 023/HVTN502): A phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef trivalent vaccine," 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3 to 6 February 2008.
19. Establishing a Scientific Agenda for Laboratory Studies to Seek Better Understanding of the STEP Trial Results, www.hvtn.org/science/step_review. html
20. M. Robertson et al., "Immunological characterization of subjects from the STEP Study: A phase IIB test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef trivalent vaccine," 15th Conference on Retroviruses and Opportunistic Infections Boston, MA, 3 to 6 February 2008.
21. Summit on HIV Vaccine Research and Development, Bethesda, MD, 25 March 2008 (NIAID, Bethesda, MD); http://www3.niaid.nih.gov/news/events/ summitHIVVaccine.htm
22. J. Kaiser, Science 320, 30 (2008).
23. Request for Information (RFI): To Solicit Input and Ideas on Priorities in Basic Vaccine Discovery Research, http://grants.nih.gov/ grants/guide/notice-files/NOT-AI-08-048.html